Vasopeptidase inhibitors: Incorporation of geminal and spirocyclic substituted azepinones in mercaptoacyl dipeptides

Journal of Medicinal Chemistry

Volumn 42, Issue 2, 1999, Pages 305-311

  Robl, Jeffrey A ^a   Sulsky, Richard ^a   Sieber McMaster, Ellen ^a   Ryono, Denis E ^a   Cimarusti, Maria P ^a   Simpkins, Ligaya M ^a   Karanewsky, Donald S ^a   Chao, Sam ^a   Asaad, Magdi M ^a   Seymour, Andrea A ^a   Fox, Maxine ^a   Smith, Patricia L ^a   Trippodo, Nick C ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEXAHYDRO 6 [(2 MERCAPTO 1 OXO 3 PHENYLPROPYL)AMINO] 2,2 DIMETHYL 7 OXO 1H AZEPINE 1 ACETIC ACID; MEMBRANE METALLOENDOPEPTIDASE; METALLOPROTEINASE INHIBITOR; OMAPATRILAT; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG STRUCTURE; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; STRUCTURE ACTIVITY RELATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AZEPINES; DIPEPTIDES; MACACA FASCICULARIS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; NEPRILYSIN; PEPTIDYL-DIPEPTIDASE A; PROTEASE INHIBITORS; RATS;

EID: 0032906160     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980542f     Document Type: Article

References (26)

1. (a) Linz, W.; Wiemer, G.; Scholkens, B. A. Cardiac inhibition of angiotensin converting enzyme: role of kinins. Endothelial Cell Res. Ser. 1998, 2, 223-235.
2. (b) Sugimoto, K.; Fujimura, A. Role of bradykinin in the reduction of left ventricular hypertrophy induced by angiotensin-converting enzyme inhibitors in spontaneously hypertensive rats. Jpn. J. Pharmacol. 1998, 76, 431-434.
3. (c) Yang, X.-P.; Liu, Y.-H.; Peterson, E.; Carretero, O. A. Effect of neutral endopeptidase 24.11 inhibition on myocardial ischemia/reperfusion injury: the role of kinins. J. Cardiovasc. Pharmacol. 1997, 29, 250-256.
4. (d) Gavras, I. Bradykinin-mediated effects of ACE inhibition. Kidney Int. 1992, 42, 1020-1029.
5. (a) Robl, J. A.; Trippodo, N. C.; Petrillo, E. W. Neutral endopeptidase inhibitors and combined inhibitors of neutral endopepti-dase and angiotensin-converting enzyme. In Antihypertensive Drugs; Van Zwieten, P. A., Greenlee, W. J., Eds.; Harwood Academic Publishers: Amsterdam, 1997; pp 113-212.
6. (b) De Lombaert, S.; Chatelain, R. E.; Fink, C. E.; Trapani, A. J. Design and pharmacology of dual angiotensin-converting enzyme and neutral endopeptidase inhibitors. Curr. Pharm. Des. 1996, 2, 443-462.
7. (c) Fink, C. A. Recent advances in the development of dual angiotensin-converting enzyme and neutral endopeptidase inhibitors. Exp. Opin. Ther. Patents 1996, 6, 1147-1164.
8. (d) Flynn, G. A.; French, J. F.; Dage, R. C. Dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase: design and therapeutic rationale. In Hypertension: Pathophysiology, Diagnosis, and Management, 2nd ed.; Laragh, J. H., Brenner, B. M., Eds.; Raven Press Ltd.: New York, 1995; pp 3099-3114.
9. Robl, J. A.; Sun, C.-Q.; Stevenson, J.; Ryono, D. E.; Simpkins, L. M.; Cimarusti, M. P.; Dejneka, T.; Slusarchyk, W. A.; Chao, S.; Stratton, L.; Misra, R. M.; Bednarz, M. S.; Asaad, M. M.; Cheung, H. S.; Abboa-Offei, B. E.; Smith, P. L.; Mathers, P. D.; Fox, M.; Schaeffer, T. R.; Seymour, A. A.; Trippodo, N. C. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J. Med. Chem. 1997, 40, 1570-1577.
10. Trippodo, N. C.; Robl, J. A.; Asaad, M. M.; Fox, M.; Panchal, B.; Schaeffer, T. R. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am. J. Hypertens. 1998, 11, 363-372.
11. (a) Liao, W.; Delaney, C.; Smith, R.; Lubin, S.; McNulty, S.; Davis, K.; Meier, A.; Uderman, H. Supine mean arterial blood pressure (MAP) lowering and oral tolerance of BMS-186716, a new dual metalloprotease inhibitor of angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP), in healthy male subjects (abst.). Clin. Pharmacol. Ther. 1997, 61, 229.
12. (b) Vesterqvist, O.; Liao, W.; Manning, J. A.; Uderman, H.; Delaney. C.; Beierle, F.; Swanson, B. N. Effects of BMS-186716, a new dual metalloprotease inhibitor, on pharmacodynamic markers of neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE), in healthy male subjects (abst.). Clin. Pharmacol. Ther. 1997, 61, 230.
13. (a) Delaney, N. G.; Barrish, J. C.; Neubeck, R.; Natarajan, S. I.; Rovnyak, G. C.; Huber, G.; Murugesan, N.; Girotra, R.; Sieber-McMaster, E.; Robl, J. A.; Asaad, M.; Cheung, H. S.; Bird, E.; Waldron, T.; Petrillo, E. W. Mercaptoacyl dipeptides as dual inhibitors of angiotension converting enzyme and neutral endopeptidase. Preliminary structure-activity studies. BioMed. Chem. Lett. 1994, 4, 1783-1788.
14. (b) Robl, J. A.; Simpkins, L. M.; Stevenson, J.; Sun, C. Q.; Murugesan, N.; Barrish, J. C.; Asaad, M. M.; Bird, J. E.; Schaeffer, T. R.; Trippodo, N. R.; Petrillo, E. W.; Karanewsky, D. S. Dual metalloprotease inhibitors. I. Constrained peptidomimetics of mercaptoacyl dipeptides. BioMed. Chem. Lett. 1994, 4, 1789-1794.
15. (c) Robl, J. A.; Simpkins, L. M.; Sulsky, R.; Sieber-McMaster, E.; Stevenson, J.; Kelly. Y. F.; Sun, C. Q.; Misra, R. N.; Ryono, D. E.; Asaad, M. M.; Bird, J. E.; Trippodo, N. C.; Karanewsky, D. S. Dual metalloprotease inhibitors. II. Effect of substitution and stereochemistry on benzazepinone based mercaptoacetyls. BioMed Chem. Lett. 1994, 4, 1795-1800.
16. (d) Robl, J. A.; Sun, C. Q.; Simpkins, L. M.; Ryono, D. E.; Barrish, J. C.; Karanewsky, D. S.; Asaad, M. M.; Schaeffer, T. R.; Trippodo, N. C. Dual metalloprotease inhibitors. III. Utilization of bicyclic and monocyclic diazepinone based mercaptoacetyls. BioMed. Chem. Lett 1994, 4, 2055-2060.
17. (e) Das, J.; Robl, J. A.; Reid, J. A.; Sun, C.-Q.; Misra, R. N.; Brown, B. R.; Ryono, D. E.; Asaad, M. M.; Bird, J. E.; Trippodo, N. C.; Petrillo, E. W.; Karanewsky, D. S. Dual metalloprotease inhibitors. IV. Utilization of thiazepines and thiazines as constrained peptidomimetic surrogates in mercaptoacyl dipeptides. BioMed. Chem. Lett. 1994, 4, 2193-2198.
18. (f) Slusarchyk, W. A.; Robl, J. A.; Taunk, P. C.; Asaad, M. M.; Bird, J. E.; DiMarco, P. Y. Dual metalloprotease inhibitors. V. utilization of bicyclic azepinonethiazolidines and azepinonetetrahydrothiazines in constrained peptidomimetics of mercaptoacyl dipeptides. BioMed. Chem. Lett. 1995, 5, 753-758.
19. Robl, J. A.; Cimarusti, M. P.; Simpkins, L. M.; Brown, B. B.; Ryono, D. E.; Bird, J. E.; Asaad, M. M.; Schaeffer, T. R.; Trippodo, N. C. Dual metalloprotease inhibitors 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors. J. Med. Chem. 1996, 39, 494-502.
20. Robl, J. A.; Sieber-McMaster, E.; Sulsky, R. Synthetic routes for the generation of 7,7-dialkyl azepin-2-ones. Tetrahedron Lett. 1996, 37, 8985-8988.
21. 3Al in toluene solution failed to give the desired adduct cleanly.
22. 4: A nonbasic and highly selective Grignard analogue. Tetrahedron 1986, 42, 2931-2935. We also found it convenient to perform this reaction using dichloromethane as solvent which usually affords better reaction homogeneity.
23. Koziara, A.; Zwierzak, A. Iminophosphorane-mediated transformation of tertiary alcohols into tert-alkylamines and their N-phosphorylated derivatives. Tetrahedron Lett. 1987, 28, 6513-6516.
24. Robl, J. A.; Cimarusti, M. P. A synthetic route for the generation of C-7 substituted azepinones. Tetrahedron Lett. 1994, 35, 1393-1396.
25. See: Trippodo, N. C.; Robl, J. A.; Asaad, M. M.; Bird, J. E.; Panchal, B. C.; Schaeffer, T. R.; Fox, M.; Giancarli, M. R.; Cheung, H. S. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin converting enzyme BMS-182657 in experimental hypertension and heart failure. J. Pharmacol. Exp. Ther. 1995, 275, 745-752, as well as refs 3 and 4 for a description of the AI pressor response assay and the 1-K DOCA salt rat assay. The SHR assay was performed as described in ref 4 utilizing the telemetry techniques outlined by Bazil, M. K.; Krulan, C.; Webb, R. L. Telemetric monitoring of cardiovascular parameters in conscious spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 1993, 22, 897-905.
26. See: Trippodo, N. C.; Robl, J. A.; Asaad, M. M.; Bird, J. E.; Panchal, B. C.; Schaeffer, T. R.; Fox, M.; Giancarli, M. R.; Cheung, H. S. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin converting enzyme BMS-182657 in experimental hypertension and heart failure. J. Pharmacol. Exp. Ther. 1995, 275, 745-752, as well as refs 3 and 4 for a description of the AI pressor response assay and the 1-K DOCA salt rat assay. The SHR assay was performed as described in ref 4 utilizing the telemetry techniques outlined by Bazil, M. K.; Krulan, C.; Webb, R. L. Telemetric monitoring of cardiovascular parameters in conscious spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 1993, 22, 897-905.